Abstract
Alzheimer’s disease (AD) is strictly connected with aging and frailty. Although dementia contributes to frailty, it is not well established whether AD patients could be per se defined “frail”. At the same time, it is not known whether among AD patients, which are a heterogeneous group of patients, it is possible to identify a subgroup of frail individuals. In this work we sought indices useful to identify “the frail AD”. To do this we evaluated disease progression rate and response to pharmacological treatment (Mini Mental State Examination evaluation), cerebrospinal fluid biomarkers (amyloid-β42, total-tau and phospho-tau) levels, inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) in a group of patients with a diagnosis of probable AD. Our results describe the clinical profile of patients which could be considered as non-responders and rapidly progressive AD. In the absence of other indices we conclude that patients with these features could well be considered “frail” among AD.
Keywords: Alzheimer’s disease, frailty, tau protein, amyloid-β42, mini mental state examination.
CNS & Neurological Disorders - Drug Targets
Title:Frailty Among Alzheimer’s Disease Patients
Volume: 12 Issue: 4
Author(s): Giacomo Koch, Lorena Belli, Temistocle Lo Giudice, Francesco Di Lorenzo, Giulia Maria Sancesario, Roberto Sorge, Sergio Bernardini and Alessandro Martorana
Affiliation:
Keywords: Alzheimer’s disease, frailty, tau protein, amyloid-β42, mini mental state examination.
Abstract: Alzheimer’s disease (AD) is strictly connected with aging and frailty. Although dementia contributes to frailty, it is not well established whether AD patients could be per se defined “frail”. At the same time, it is not known whether among AD patients, which are a heterogeneous group of patients, it is possible to identify a subgroup of frail individuals. In this work we sought indices useful to identify “the frail AD”. To do this we evaluated disease progression rate and response to pharmacological treatment (Mini Mental State Examination evaluation), cerebrospinal fluid biomarkers (amyloid-β42, total-tau and phospho-tau) levels, inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) in a group of patients with a diagnosis of probable AD. Our results describe the clinical profile of patients which could be considered as non-responders and rapidly progressive AD. In the absence of other indices we conclude that patients with these features could well be considered “frail” among AD.
Export Options
About this article
Cite this article as:
Koch Giacomo, Belli Lorena, Giudice Lo Temistocle, Lorenzo Di Francesco, Sancesario Maria Giulia, Sorge Roberto, Bernardini Sergio and Martorana Alessandro, Frailty Among Alzheimer’s Disease Patients, CNS & Neurological Disorders - Drug Targets 2013; 12 (4) . https://dx.doi.org/10.2174/1871527311312040010
DOI https://dx.doi.org/10.2174/1871527311312040010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cellular and Molecular Basis of Health Benefits of Grape Seed Proanthocyanidin Extract
Current Pharmaceutical Biotechnology Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology The Location of Vascular Flap is Related with Daily Activity Patterns in Non-traumatic Acute Aortic Syndrome in a Chinese Population
Current Signal Transduction Therapy Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets Latest Advances in Hydrogel-Based Drug Delivery Systems for Optimization of Metabolic Syndrome Treatment
Current Medicinal Chemistry Benzothiazole Derivatives: Novel Inhibitors of Methylglyoxal Mediated Glycation of Proteins In Vitro
Medicinal Chemistry Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design The Importance of Gender Differences in the Diagnosis and Management of Cardiovascular Disease
Current Pharmaceutical Design Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Fishing for Age-Related Visual System Mutants: Behavioral Screening of Retinal Degeneration Genes in Zebrafish
Current Aging Science Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Case-Control Study Investigating the Effect of MTHFR C677T Variant on Performance of Elite Athletes
Endocrine, Metabolic & Immune Disorders - Drug Targets Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis
Current Pharmaceutical Design Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism